RE:RE:RE:Citizens Stash dealBrands, genetics, quality supply.
That is what they paid for. 40m is a fine price, especially when much of it is stock based acquisition.
The next 4 quarters will show (not "may") sequential revenue growth, ebitda growth, and positive momentum. Valens will do 125 to 150mil in 2022 in the bag. Stretch 150 to 180m.
-Pommies
-Nasdaq. (access to the stock by US institutions).
-Further partnership agreements.
Looking for positive momentum demonstrated from Green Roads.
Other factors are mainly rising tide events- but will be positive.
-Acquisitions by larger brands entering the space. They're coming.
-US legalization (not if, when).
-Extreme negative market sentiment based on the weak, and discounting the strong (insert Trulieve, Curaleaf, Green Thumb, Ayr...... ETC ETC).
-Consolidation. Any company like Valens (sub 1 bil market cap, with brands, genetics, manufacturing and distribution), is a take out target.
Stock is on sale. No doubt.